Our results showed an increasing trend in the number of CA indications used in China in recent years, reflecting the NMPA's regulatory flexibility for serious and life-threatening cancers without available therapy.
← all excerpts
Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022.
1
—
—